Key result
Adding dihydroergotamine to low-dose heparin fails to reduce venous thrombosis after elective hip replacement.
Why the study?
The comparative efficacy of low dose heparin alone versus low dose heparin combined with dihydroergotamine for prevention of venous thrombosis after elective hip replacement was uncertain.
Does the addition of dihydroergotamine to low dose heparin prevent venous thrombosis in patients having elective hip replacement?
RCT (n=117)
Double-blind
randomised
Does the addition of dihydroergotamine to low dose heparin prevent venous thrombosis in patients having elective hip replacement?
The addition of dihydroergotamine to low dose heparin does not significantly reduce the incidence of venous thrombosis compared to heparin alone after elective hip replacement.
Answers are grounded in this paper and cite their sources.
No benefit from adding dihydroergotamine to low-dose heparin after hip replacement; supports heparin monotherapy for VTE prophylaxis in elective orthopedic surgery.
We report the results of a double-blind, randomised trial of venous thrombosis (VT) prevention in 117 patients having elective hip replacement where low dose heparin alone (5,000 IU sodium heparin given subcutaneously [sc] 8 hourly until the seventh postoperative day) was compared with low dose heparin plus dihydroergotamine (DHE; 0.5 mg, given 8 hourly by sc injection). The trial end point consisted of VT discovered through bilateral ascending venography done routinely on the seventh postoperative day. VT developed in 34% of patients given heparin/DHE (95% confidence interval = 22% - 47%) compared with 24% in those given low dose heparin alone (95% confidence interval = 14% - 37%; p = 0.34), difference = 10% (95% confidence interval = -7% to +26%). Corresponding figures for the incidence of proximal (above-knee) thrombosis were 17% and 14% (95% confidence intervals = 8% - 29% and 6% - 25% respectively). These results are discussed in the context of a detailed overview of published evidence concerning VT prevention with heparin/DHE after hip replacement and we conclude it is unlikely that heparin/DHE is markedly superior to low dose heparin alone in this clinical setting.
No takes yet. Share an insight, caveat, or question.
Gallus et al. (1992) conducted an RCT in elective hip replacement (n=117). low dose heparin plus dihydroergotamine (DHE) vs. low dose heparin alone (5,000 IU subcutaneously 8 hourly) was evaluated on venous thrombosis (VT) discovered through bilateral ascending venography on the seventh postoperative day (difference 10%, 95% CI -7 to 26, p=0.34). Low dose heparin plus dihydroergotamine did not reduce venous thrombosis compared to heparin alone after elective hip replacement.
Synapse has enriched 10 related papers. Consider them for comparative context: